Assembly Biosciences, Inc.
ASMB
$10.03
$0.0250.25%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 28.52M | 28.33M | 21.48M | 12.95M | 7.16M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 28.52M | 28.33M | 21.48M | 12.95M | 7.16M |
| Cost of Revenue | 55.93M | 52.66M | 49.97M | 46.23M | 48.90M |
| Gross Profit | -27.41M | -24.33M | -28.49M | -33.28M | -41.74M |
| SG&A Expenses | 18.01M | 22.11M | 22.04M | 22.53M | 22.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 73.94M | 74.77M | 72.01M | 68.76M | 71.81M |
| Operating Income | -45.42M | -46.44M | -50.53M | -55.82M | -64.65M |
| Income Before Tax | -39.85M | -40.37M | -45.17M | -51.32M | -61.20M |
| Income Tax Expenses | 330.00K | 439.00K | 439.00K | 33.00K | 33.00K |
| Earnings from Continuing Operations | -40.18 | -40.80 | -45.61 | -51.36 | -61.23 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.18M | -40.80M | -45.61M | -51.36M | -61.23M |
| EBIT | -45.42M | -46.44M | -50.53M | -55.82M | -64.65M |
| EBITDA | -45.29M | -46.26M | -50.27M | -55.46M | -64.20M |
| EPS Basic | -6.73 | -7.21 | -8.98 | -10.89 | -13.69 |
| Normalized Basic EPS | -4.17 | -4.45 | -5.57 | -6.80 | -8.55 |
| EPS Diluted | -6.73 | -7.21 | -8.98 | -10.89 | -13.69 |
| Normalized Diluted EPS | -4.17 | -4.45 | -5.57 | -6.80 | -8.55 |
| Average Basic Shares Outstanding | 24.01M | 22.80M | 20.83M | 19.54M | 18.31M |
| Average Diluted Shares Outstanding | 24.01M | 22.80M | 20.83M | 19.54M | 18.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |